SABS

Company Overview — What Does SAB Biotherapeutics, Inc. Do?

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota. SAB Biotherapeutics, Inc. (SABS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Eddie J. Sullivan and employs approximately 140 people. With a market capitalization of $272M, SABS is one of the notable companies in the Healthcare sector.

SAB Biotherapeutics, Inc. (SABS) Stock Rating — Reduce (April 2026)

As of April 2026, SAB Biotherapeutics, Inc. receives a Reduce rating with a composite score of 32.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SABS ranks #2,861 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SAB Biotherapeutics, Inc. ranks #401 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SABS Stock Price and 52-Week Range

SAB Biotherapeutics, Inc. (SABS) currently trades at $3.75. The stock lost $0.08 (2.1%) in the most recent trading session. The 52-week high for SABS is $6.60, which means the stock is currently trading -43.2% from its annual peak. The 52-week low is $1.00, putting the stock 275.0% above its annual trough. Recent trading volume was 198K shares, suggesting relatively thin trading activity.

Is SABS Overvalued or Undervalued? — Valuation Analysis

SAB Biotherapeutics, Inc. (SABS) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 13.36x, compared to the Healthcare sector average of 23.63x — a discount of 43%. The price-to-book ratio stands at 1.74x, versus the sector average of 2.75x. On an enterprise value basis, SABS trades at 0.11x EV/EBITDA, versus 6.34x for the sector.

At current multiples, SAB Biotherapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

SAB Biotherapeutics, Inc. Profitability — ROE, Margins, and Quality Score

SAB Biotherapeutics, Inc. (SABS) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 13.1%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 11.5% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SABS Debt, Balance Sheet, and Financial Health

SAB Biotherapeutics, Inc. has a debt-to-equity ratio of 14.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 9.46x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $29M.

SABS has a beta of 0.93, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for SAB Biotherapeutics, Inc. is 36/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

SAB Biotherapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, SAB Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $0.22. Net income for the quarter was $20M. Operating income came in at $-44M.

In FY 2025, SAB Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $0.22. Net income for the quarter was $13M. Operating income came in at $-49M.

In Q3 2025, SAB Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $0.50. Net income for the quarter was $45M. Operating income came in at $-13M.

In Q2 2025, SAB Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.09. Net income for the quarter was $-10M. Operating income came in at $-10M.

Over the past 8 quarters, SAB Biotherapeutics, Inc. has experienced revenue contraction from $263,137 to $0. Investors analyzing SABS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SABS Dividend Yield and Income Analysis

SAB Biotherapeutics, Inc. (SABS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SABS Momentum and Technical Analysis Profile

SAB Biotherapeutics, Inc. (SABS) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 9/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SABS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SAB Biotherapeutics, Inc. (SABS) ranks #401 out of 838 stocks based on the Blank Capital composite score. This places SABS in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SABS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SABS vs S&P 500 (SPY) comparison to assess how SAB Biotherapeutics, Inc. stacks up against the broader market across all factor dimensions.

SABS Next Earnings Date

No upcoming earnings date has been announced for SAB Biotherapeutics, Inc. (SABS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SABS? — Investment Thesis Summary

The quantitative profile for SAB Biotherapeutics, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 36/100) increases portfolio risk.

In summary, SAB Biotherapeutics, Inc. (SABS) earns a Reduce rating with a composite score of 32.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SABS stock.

Related Resources for SABS Investors

Explore more research and tools: SABS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SABS head-to-head with peers: SABS vs AZN, SABS vs SLGL, SABS vs VMD.